News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Update on Pharmaxis CEO
The Chairman of the Pharmaxis Ltd Board, Mr Denis Hanley advises that Pharmaxis Chief Executive Officer, Dr Alan Robertson, continues to recover after undergoing a medical procedure three weeks ago.
Read full media release - pdf
Pharmaxis Announces Results for Second Phase III Trial of Bronchitol in Cystic Fibrosis
Pharmaxis is pleased to announce top line results from the second large-scale global Phase III trial (CF302) of Bronchitol® (mannitol inhalation powder) in patients with cystic fibrosis (CF).
The results support the early and sustained improvement in lung function in cystic fibrosis patients seen in the first phase III study (CF301) and Pharmaxis will now move forward to meet the U.S. Food & Drug Administration (FDA) later this year to discuss a New Drug Application (NDA) for Bronchitol.
Read full media release - pdf
Investor Conference Call - Clinical Trial Results
Pharmaxis Ltd expects to complete its analysis and announce the results of its second international Phase III clinical trial of Bronchitol in patients with cystic fibrosis prior to the end of today, 22 June 2010. The announcement will have the effect of lifting the current trading halt over the company's shares.